Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05478538 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Conditions Studied
Interventions
- PROCEDURE Core Needle, Forceps, or Punch Biopsy
Study Locations (7)
Texas
- JPS Health Network — Fort Worth
- Baylor Scott & White Research Institute — Temple
California
- UCLA Medical Center — Los Angeles
Maryland
- James M Stockman Cancer Institute — Frederick
New York
- New York Cancer & Blood Specialists — Shirley
North Carolina
- University of North Carolina at Chapel Hill — Chapel Hill
Ohio
- Gabrail Cancer Center — Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478538
The ClinicalTrials.gov registry entry for NCT05478538 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elephas, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with NSCLC (Non-small Cell Lung Cancer) appearing as the primary indexed condition, and to 1 intervention — of which Core Needle, Forceps, or Punch Biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05478538 reports 7 study locations spanning 6 distinct geographic areas — top geographies include Texas, California, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05478538 about?
NCT05478538 is a clinical study titled "Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform". The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
What is the current status of trial NCT05478538?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-01-31. Estimated completion is 2026-12.
What conditions does trial NCT05478538 study?
This clinical trial studies the following conditions: NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05478538?
The interventions under investigation include: Core Needle, Forceps, or Punch Biopsy (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05478538?
This trial is sponsored by Elephas, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05478538 being conducted?
This trial has 7 study locations across California, Maryland, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.